Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DaunoXome (NeXstar Pharmaceuticals, 8459a2)
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
DaunoXome is a liposomal formulation of daunorubicin citrate, an anthracycline chemotherapy agent. Developed by NeXstar Pharmaceuticals, it was specifically designed to improve the therapeutic index of daunorubicin by utilizing a liposomal delivery system. This nanoparticle modality enhances drug delivery to tumor tissues, such as those in Kaposi's sarcoma, by exploiting the increased permeability of tumor vasculature while simultaneously reducing systemic toxicities, particularly cardiotoxicity, compared to conventional daunorubicin. The drug exerts its antineoplastic effect by intercalating between DNA base pairs and inhibiting topoisomerase II, thereby disrupting DNA replication and RNA synthesis. It is primarily indicated as a first-line cytotoxic therapy for advanced, HIV-associated Kaposi's sarcoma.
- Brand names
- DaunoXome
- Other names
- daunorubicin citrate liposome injectionliposomal daunorubicindaunorubicin (liposomal)
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on DaunoXome (NeXstar Pharmaceuticals, 8459a2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DaunoXome (NeXstar Pharmaceuticals, 8459a2).